Arrowhead Pharmaceuticals (ARWR) Operating Expenses (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Operating Expenses came in at $215.0 million in Q1 2026, up 33.12% YoY from $161.5 million in Q1 2025, and down 3.69% on a QoQ basis from $223.2 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Operating Expenses (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Operating Expenses data on file, last reported at $215.0 million in Q1 2026.
- Quarterly Operating Expenses rose 33.12% year-over-year to $215.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $843.9 million (up 27.14% YoY) and the FY2025 annual result came in at $731.1 million, up 20.92% from the prior year.
- Operating Expenses fell to $215.0 million in Q1 2026, from $223.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $223.2 million in Q4 2025 to a low of $98.1 million in Q1 2023.
- A 5-year average of $150.0 million and a median of $140.1 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses soared 80.61% — and 2023, when it slipped 11.02%.
- Tracing ARWR's Operating Expenses over 5 years: stood at $104.7 million in 2022, then soared by 33.83% to $140.1 million in 2023, then rose by 17.0% to $163.9 million in 2024, then jumped by 36.19% to $223.2 million in 2025, then decreased by 3.69% to $215.0 million in 2026.
- The last three Operating Expenses figures came in at $215.0 million (Q1 2026), $223.2 million (Q4 2025), and $212.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | 245.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 245.35 Mn |
| Mar 31, 2026 | 215.00 Mn |
| Dec 31, 2025 | 223.22 Mn |
| Sep 30, 2025 | 212.37 Mn |
| Jun 30, 2025 | 193.32 Mn |
| Mar 31, 2025 | 161.51 Mn |
| Dec 31, 2024 | 163.91 Mn |
| Sep 30, 2024 | 162.20 Mn |
| Jun 30, 2024 | 176.14 Mn |
| Mar 31, 2024 | 126.19 Mn |
| Dec 31, 2023 | 140.10 Mn |
| Sep 30, 2023 | 124.43 Mn |
| Jun 30, 2023 | 118.53 Mn |
| Mar 31, 2023 | 98.10 Mn |
| Dec 31, 2022 | 104.68 Mn |
| Sep 30, 2022 | 115.41 Mn |
| Jun 30, 2022 | 105.32 Mn |
| Mar 31, 2022 | 110.25 Mn |
| Dec 31, 2021 | 90.76 Mn |
| Sep 30, 2021 | 103.17 Mn |